^
    Back
    Association details:
    Biomarker:TMB-H
    Cancer:Solid Tumor
    Drug:Tyvyt (sintilimab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    IBI308 in Subjects With Advanced/Metastatic Solid Malignancies

    Excerpt:
    ...Cohort 1: Advanced/metastatic cancers with high TMB expression i....
    Trial ID:
    NCT03568539
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Am J Cancer Res
    Title:

    Assessment of TMB, PD-L1, and lymphocyte to monocyte ratio as predictive potential in a phase Ib study of sintilimab in patients with advanced solid tumors

    Published date:
    09/15/2021
    Excerpt:
    This phase Ib study included six cohorts. Cohort A-C were sintilimab monotherapy settings, and enrolled pretreated patients (2/3 L cohorts)….157 patients had available TMB scores, and in 2/3 L cohorts, patients in the high TMB groups (TMB≥10) showed a longer progression-free survival (PFS) and overall survival (OS) than those in the low TMB groups (TMB<10).
    Trial ID:
    NCT02937116